[{"id":"a2748e44-3f76-4ef4-9c24-1b7476039a69","acronym":"","url":"https://clinicaltrials.gov/study/NCT05554393","created_at":"2022-09-26T14:56:10.693Z","updated_at":"2025-02-25T13:49:33.606Z","phase":"Phase 2","brief_title":"Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)","source_id_and_acronym":"NCT05554393","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • FLT3 • NPM1 • RUNX1 • ASXL1 • RARA • RUNX1T1 • PML • CEBPA","pipe":" | ","alterations":" TP53 mutation • FLT3-ITD mutation • NPM1 mutation • RUNX1 mutation • ASXL1 mutation • FLT3-TKD mutation","tags":["TP53 • FLT3 • NPM1 • RUNX1 • ASXL1 • RARA • RUNX1T1 • PML • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3-ITD mutation • NPM1 mutation • RUNX1 mutation • ASXL1 mutation • FLT3-TKD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • azacitidine • daunorubicin • Starasid (cytarabine ocfosfate)"],"overall_status":"Recruiting","enrollment":" Enrollment 153","initiation":"Initiation: 09/13/2024","start_date":" 09/13/2024","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-20"},{"id":"c2fb4b7e-7e4c-490d-87bd-2814f4996b26","acronym":"","url":"https://clinicaltrials.gov/study/NCT05886049","created_at":"2023-06-02T14:06:05.454Z","updated_at":"2025-02-25T13:55:14.969Z","phase":"Phase 1","brief_title":"Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene","source_id_and_acronym":"NCT05886049","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" FLT3 • NPM1 • KMT2A","pipe":" | ","alterations":" FLT3-ITD mutation • FLT3 mutation • NPM1 mutation • MLL mutation","tags":["FLT3 • NPM1 • KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • FLT3 mutation • NPM1 mutation • MLL mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e daunorubicin • Revuforj (revumenib) • Starasid (cytarabine ocfosfate)"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 06/20/2024","start_date":" 06/20/2024","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-20"},{"id":"6280dfa5-ede9-4d89-a587-10249cd79abf","acronym":"AGORA-1","url":"https://clinicaltrials.gov/study/NCT05199051","created_at":"2022-01-20T15:53:56.079Z","updated_at":"2025-02-25T14:02:40.845Z","phase":"Phase 2","brief_title":"A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults with FLT3-ITD Relapse/refractory (R/R) AML","source_id_and_acronym":"NCT05199051 - AGORA-1","lead_sponsor":"Centre Antoine Lacassagne","biomarkers":" FLT3 • CD33","pipe":" | ","alterations":" FLT3-ITD mutation • FLT3-TKD mutation • CD33 positive","tags":["FLT3 • CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • FLT3-TKD mutation • CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Xospata (gilteritinib) • Mylotarg (gemtuzumab ozogamicin)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 06/03/2023","start_date":" 06/03/2023","primary_txt":" Primary completion: 03/15/2027","primary_completion_date":" 03/15/2027","study_txt":" Completion: 03/15/2027","study_completion_date":" 03/15/2027","last_update_posted":"2025-02-19"},{"id":"ae37ad26-112d-406e-b4ec-b9bd80c911c9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05292664","created_at":"2022-03-23T13:53:35.750Z","updated_at":"2025-02-25T14:08:44.222Z","phase":"Phase 1","brief_title":"Venetoclax Basket Trial for High Risk Hematologic Malignancies","source_id_and_acronym":"NCT05292664","lead_sponsor":"Andrew E. Place, MD","biomarkers":" FLT3 • ABL1 • BCR • BCL2 • KMT2A • IKZF1","pipe":" | ","alterations":" KMT2A rearrangement • ABL1 fusion","tags":["FLT3 • ABL1 • BCR • BCL2 • KMT2A • IKZF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KMT2A rearrangement • ABL1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • doxorubicin hydrochloride • azacitidine • vincristine • leucovorin calcium • Asparlas (calaspargase pegol-mknl) • dexrazoxane"],"overall_status":"Recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 03/29/2023","start_date":" 03/29/2023","primary_txt":" Primary completion: 07/02/2026","primary_completion_date":" 07/02/2026","study_txt":" Completion: 07/02/2028","study_completion_date":" 07/02/2028","last_update_posted":"2025-02-17"},{"id":"9480eee5-c88d-4aa5-a04a-bfe171590b90","acronym":"INCB 84344-102","url":"https://clinicaltrials.gov/study/NCT03934372","created_at":"2021-01-18T19:22:38.750Z","updated_at":"2025-02-25T14:40:12.243Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors","source_id_and_acronym":"NCT03934372 - INCB 84344-102","lead_sponsor":"Incyte Biosciences International Sàrl","biomarkers":" FLT3 • ABL1 • BCR • RET • FGFR • BLM","pipe":" | ","alterations":" EGFR mutation • KIT mutation • FGFR mutation • RET mutation","tags":["FLT3 • ABL1 • BCR • RET • FGFR • BLM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • KIT mutation • FGFR mutation • RET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Iclusig (ponatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/29/2020","start_date":" 01/29/2020","primary_txt":" Primary completion: 01/30/2026","primary_completion_date":" 01/30/2026","study_txt":" Completion: 01/30/2026","study_completion_date":" 01/30/2026","last_update_posted":"2025-02-14"},{"id":"2215a379-2b74-4e43-b073-534f2995d428","acronym":"","url":"https://clinicaltrials.gov/study/NCT06001788","created_at":"2023-08-21T14:08:48.344Z","updated_at":"2025-02-25T15:13:42.778Z","phase":"Phase 1","brief_title":"Safety and Tolerability of Ziftomenib Combinations in Patients with Relapsed/Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT06001788","lead_sponsor":"Kura Oncology, Inc.","biomarkers":" FLT3 • NPM1 • KMT2A","pipe":" | ","alterations":" FLT3 mutation • NPM1 mutation • KMT2A rearrangement • KMT2A mutation • MLL mutation","tags":["FLT3 • NPM1 • KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • NPM1 mutation • KMT2A rearrangement • KMT2A mutation • MLL mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Xospata (gilteritinib) • idarubicin hydrochloride • Komzifti (ziftomenib) • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 171","initiation":"Initiation: 02/22/2024","start_date":" 02/22/2024","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2025-02-13"},{"id":"460f1e61-72a2-48bb-a37c-e804016f6240","acronym":"NCI-2021-06095","url":"https://clinicaltrials.gov/study/NCT05010122","created_at":"2021-08-18T15:53:42.501Z","updated_at":"2025-02-25T15:12:15.219Z","phase":"Phase 1/2","brief_title":"ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome","source_id_and_acronym":"NCT05010122 - NCI-2021-06095","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation • FLT3 mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Xospata (gilteritinib) • Inqovi (decitabine/cedazuridine)"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 07/08/2021","start_date":" 07/08/2021","primary_txt":" Primary completion: 01/30/2026","primary_completion_date":" 01/30/2026","study_txt":" Completion: 01/30/2026","study_completion_date":" 01/30/2026","last_update_posted":"2025-02-13"},{"id":"99225106-dfaa-4574-8f8a-c62a8252d206","acronym":"","url":"https://clinicaltrials.gov/study/NCT04293562","created_at":"2021-01-18T20:50:03.431Z","updated_at":"2025-02-25T15:11:29.634Z","phase":"Phase 3","brief_title":"A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations","source_id_and_acronym":"NCT04293562","lead_sponsor":"Children's Oncology Group","biomarkers":" FLT3","pipe":"","alterations":" ","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xospata (gilteritinib) • etoposide IV • methotrexate • Mylotarg (gemtuzumab ozogamicin) • Vyxeos (cytarabine/daunorubicin liposomal formulation) • mitoxantrone • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • Erwinase (erwinia asparaginase) • Kidrolase (L-asparaginase) • Leunase (L-asparaginase) • Spectrila (asparaginase Escherichia coli) • Starasid (cytarabine ocfosfate) • dexrazoxane"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1186","initiation":"Initiation: 07/21/2020","start_date":" 07/21/2020","primary_txt":" Primary completion: 09/30/2027","primary_completion_date":" 09/30/2027","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-13"},{"id":"f18181fc-ba3a-410b-9369-091830924976","acronym":"","url":"https://clinicaltrials.gov/study/NCT05457556","created_at":"2022-09-07T16:55:34.255Z","updated_at":"2025-02-25T15:12:56.234Z","phase":"Phase 3","brief_title":"Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome","source_id_and_acronym":"NCT05457556","lead_sponsor":"Children's Oncology Group","biomarkers":" FLT3 • ABL1 • BCR • NPM1 • HLA-DRB1 • CEBPA • HLA-DQB1 • HLA-B • HLA-C","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3 • ABL1 • BCR • NPM1 • HLA-DRB1 • CEBPA • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • methotrexate • melphalan • Truxima (rituximab-abbs) • fludarabine IV • thiotepa • busulfan • Mabtas (rituximab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 435","initiation":"Initiation: 03/15/2023","start_date":" 03/15/2023","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-02-13"},{"id":"e5e2b950-7554-4958-b2db-713f66c51761","acronym":"","url":"https://clinicaltrials.gov/study/NCT03280030","created_at":"2021-01-18T16:11:51.281Z","updated_at":"2025-02-25T15:42:59.213Z","phase":"Phase 2","brief_title":"A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML","source_id_and_acronym":"NCT03280030","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" FLT3 • PML","pipe":" | ","alterations":" FLT3 mutation","tags":["FLT3 • PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • midostaurin • daunorubicin"],"overall_status":"Completed","enrollment":" Enrollment 67","initiation":"Initiation: 04/06/2018","start_date":" 04/06/2018","primary_txt":" Primary completion: 11/14/2022","primary_completion_date":" 11/14/2022","study_txt":" Completion: 11/14/2022","study_completion_date":" 11/14/2022","last_update_posted":"2025-02-11"},{"id":"e3936c5c-e8c6-4488-bd75-cc3cc84c9df4","acronym":"NCI-2018-01789","url":"https://clinicaltrials.gov/study/NCT03661307","created_at":"2021-01-18T17:57:55.790Z","updated_at":"2025-02-25T15:25:53.725Z","phase":"Phase 1/2","brief_title":"Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome","source_id_and_acronym":"NCT03661307 - NCI-2018-01789","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • FLT3","pipe":" | ","alterations":" TP53 mutation • FLT3-ITD mutation • FLT3 mutation • TP53 deletion","tags":["TP53 • FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3-ITD mutation • FLT3 mutation • TP53 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • Vanflyta (quizartinib) • decitabine"],"overall_status":"Recruiting","enrollment":" Enrollment 73","initiation":"Initiation: 10/31/2018","start_date":" 10/31/2018","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2025-02-10"},{"id":"de01f4b4-b380-45e4-a05f-0573156a9b1c","acronym":"AAML1031","url":"https://clinicaltrials.gov/study/NCT01371981","created_at":"2021-01-18T05:37:13.447Z","updated_at":"2025-02-25T16:51:07.072Z","phase":"Phase 3","brief_title":"Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia","source_id_and_acronym":"NCT01371981 - AAML1031","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • cytarabine • bortezomib • etoposide IV • daunorubicin • mitoxantrone • Kidrolase (L-asparaginase) • Leunase (L-asparaginase) • Spectrila (asparaginase Escherichia coli) • Starasid (cytarabine ocfosfate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1645","initiation":"Initiation: 06/20/2011","start_date":" 06/20/2011","primary_txt":" Primary completion: 03/31/2019","primary_completion_date":" 03/31/2019","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-04"},{"id":"727643b8-a896-41d1-b305-2893939501cb","acronym":"","url":"https://clinicaltrials.gov/study/NCT04631744","created_at":"2021-01-19T20:36:38.297Z","updated_at":"2025-02-25T17:30:30.138Z","phase":"Phase 2","brief_title":"Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)","source_id_and_acronym":"NCT04631744","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" FLT3 • NTRK2 • AXL • KDR • FLT1 • FLT4","pipe":"","alterations":" ","tags":["FLT3 • NTRK2 • AXL • KDR • FLT1 • FLT4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/03/2021","start_date":" 03/03/2021","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2025-01-31"},{"id":"cac645f6-c6a8-4650-8b7f-ccef92224e7f","acronym":"CLEV-LAM-2022","url":"https://clinicaltrials.gov/study/NCT06764459","created_at":"2025-02-25T17:34:03.148Z","updated_at":"2025-02-25T17:34:03.148Z","phase":"","brief_title":"Molecular Characterization of Patients With Acute Myeloid Leukemia and the Impact of Clonal Evolution in the Response to Therapeutic Treatments","source_id_and_acronym":"NCT06764459 - CLEV-LAM-2022","lead_sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","biomarkers":" FLT3","pipe":"","alterations":" ","tags":["FLT3"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 03/15/2023","start_date":" 03/15/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-01-30"},{"id":"b4e91c3d-4887-4ce6-b858-890536bcbb7b","acronym":"HOVON 156 AML","url":"https://clinicaltrials.gov/study/NCT04027309","created_at":"2021-01-18T19:46:07.637Z","updated_at":"2025-02-25T15:26:07.674Z","phase":"Phase 3","brief_title":"A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy","source_id_and_acronym":"NCT04027309 - HOVON 156 AML","lead_sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation • FLT3 mutation • FLT3-TKD mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • FLT3 mutation • FLT3-TKD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xospata (gilteritinib) • midostaurin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 777","initiation":"Initiation: 12/20/2019","start_date":" 12/20/2019","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 06/01/2033","study_completion_date":" 06/01/2033","last_update_posted":"2024-12-17"},{"id":"a154a323-d6ef-4152-926e-c4ab1ae75b5e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05756777","created_at":"2023-03-06T15:01:58.629Z","updated_at":"2025-02-25T15:36:05.770Z","phase":"Phase 1","brief_title":"A Study of Gilteritinib in Combination with Ivosidenib or Enasidenib in People with Acute Myeloid Leukemia (AML)","source_id_and_acronym":"NCT05756777","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" FLT3 • IDH1 • IDH2","pipe":" | ","alterations":" IDH1 mutation • IDH2 mutation • FLT3 mutation","tags":["FLT3 • IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • IDH2 mutation • FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xospata (gilteritinib) • Tibsovo (ivosidenib) • Idhifa (enasidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 06/26/2023","start_date":" 06/26/2023","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2024-11-12"},{"id":"0ab65d95-a746-4376-a36a-807e4d1f1ece","acronym":"HBO-UBC","url":"https://clinicaltrials.gov/study/NCT03739502","created_at":"2021-01-18T18:18:53.880Z","updated_at":"2025-02-25T14:15:15.599Z","phase":"Phase 2","brief_title":"A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant","source_id_and_acronym":"NCT03739502 - HBO-UBC","lead_sponsor":"University of Rochester","biomarkers":" FLT3 • ABL1 • BCR • NPM1 • CD22 • CD34 • CD79A","pipe":" | ","alterations":" FLT3-ITD mutation • NPM1 mutation","tags":["FLT3 • ABL1 • BCR • NPM1 • CD22 • CD34 • CD79A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • NPM1 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 02/28/2019","start_date":" 02/28/2019","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2024-08-19"},{"id":"fd746a04-cf2a-4fe6-8ac1-71be01980b12","acronym":"","url":"https://clinicaltrials.gov/study/NCT03016806","created_at":"2021-01-18T14:50:46.648Z","updated_at":"2025-02-25T14:14:55.178Z","phase":"Phase 1","brief_title":"Umbilical Cord Blood Transplantation From Unrelated Donors","source_id_and_acronym":"NCT03016806","lead_sponsor":"University of Rochester","biomarkers":" FLT3 • KMT2A","pipe":" | ","alterations":" MLL rearrangement • MLL rearrangement","tags":["FLT3 • KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • melphalan • fludarabine IV • busulfan"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/01/2015","start_date":" 06/01/2015","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-08-19"},{"id":"711f8265-575f-4a14-bb60-be585609d334","acronym":"","url":"https://clinicaltrials.gov/study/NCT05024994","created_at":"2021-08-27T12:53:02.872Z","updated_at":"2025-02-25T13:35:55.158Z","phase":"Phase 2","brief_title":"A Study of E7820 in People With Bone Marrow (Myeloid) Cancers","source_id_and_acronym":"NCT05024994","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" FLT3 • IDH1 • SF3B1 • SRSF2 • U2AF1 • ZRSR2","pipe":" | ","alterations":" IDH2 mutation • FLT3 mutation • SF3B1 mutation • SRSF2 mutation • U2AF1 mutation • ZRSR2 mutation","tags":["FLT3 • IDH1 • SF3B1 • SRSF2 • U2AF1 • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • FLT3 mutation • SF3B1 mutation • SRSF2 mutation • U2AF1 mutation • ZRSR2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e E7820"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 08/13/2021","start_date":" 08/13/2021","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2024-07-03"},{"id":"759ff1ab-04a0-4c37-97e3-fac717360e85","acronym":"","url":"https://clinicaltrials.gov/study/NCT06463639","created_at":"2025-02-25T15:29:08.608Z","updated_at":"2025-02-25T15:29:08.608Z","phase":"","brief_title":"FLT3 Clonal Evolution in Patients With Acute Myeloid Leukemia","source_id_and_acronym":"NCT06463639","lead_sponsor":"National Taiwan University Hospital","biomarkers":" FLT3","pipe":"","alterations":" ","tags":["FLT3"],"overall_status":"Completed","enrollment":" Enrollment 1213","initiation":"Initiation: 01/01/2022","start_date":" 01/01/2022","primary_txt":" Primary completion: 10/31/2023","primary_completion_date":" 10/31/2023","study_txt":" Completion: 06/10/2024","study_completion_date":" 06/10/2024","last_update_posted":"2024-06-19"},{"id":"55079916-4788-41a0-a5ca-a4084d122a58","acronym":"","url":"https://clinicaltrials.gov/study/NCT05024552","created_at":"2021-08-27T12:52:57.710Z","updated_at":"2024-07-02T16:34:26.210Z","phase":"Phase 1","brief_title":"Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML","source_id_and_acronym":"NCT05024552","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation • FLT3-TKD mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • FLT3-TKD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xospata (gilteritinib) • Vyxeos (cytarabine/daunorubicin liposomal formulation)"],"overall_status":"Recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 08/23/2021","start_date":" 08/23/2021","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2024-06-13"},{"id":"1d8c8a20-aa7c-47e4-aa25-c755f938afd8","acronym":"LACEWING","url":"https://clinicaltrials.gov/study/NCT02752035","created_at":"2021-01-17T17:23:14.096Z","updated_at":"2024-07-02T16:34:26.721Z","phase":"Phase 3","brief_title":"A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy","source_id_and_acronym":"NCT02752035 - LACEWING","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation • FLT3 D835 • FLT3 I836","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • FLT3 D835 • FLT3 I836"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xospata (gilteritinib) • azacitidine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 183","initiation":"Initiation: 08/01/2016","start_date":" 08/01/2016","primary_txt":" Primary completion: 03/10/2023","primary_completion_date":" 03/10/2023","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2024-06-12"},{"id":"68d8ce34-194a-45f2-9e93-7c94e62c1815","acronym":"","url":"https://clinicaltrials.gov/study/NCT02356159","created_at":"2021-01-18T11:12:44.041Z","updated_at":"2024-07-02T16:34:36.807Z","phase":"Phase 1/2","brief_title":"Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation","source_id_and_acronym":"NCT02356159","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" FLT3 • ABL1 • BCR • ASXL1 • CD34 • HLA-B • HLA-C","pipe":" | ","alterations":" Chr t(9;11)","tags":["FLT3 • ABL1 • BCR • ASXL1 • CD34 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(9;11)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • sirolimus • fludarabine IV • Kepivance (palifermin)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 09/24/2015","start_date":" 09/24/2015","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-06-10"},{"id":"75104445-162f-444f-84ea-8038034ab832","acronym":"","url":"https://clinicaltrials.gov/study/NCT02727803","created_at":"2021-01-18T13:21:10.406Z","updated_at":"2024-07-02T16:34:36.895Z","phase":"Phase 2","brief_title":"Personalized NK Cell Therapy in CBT","source_id_and_acronym":"NCT02727803","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" FLT3 • BCL2","pipe":" | ","alterations":" FLT3 mutation","tags":["FLT3 • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • clofarabine • melphalan • Truxima (rituximab-abbs) • fludarabine IV • Riabni (rituximab-arrx) • busulfan • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • Novex (rituximab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 05/19/2016","start_date":" 05/19/2016","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 05/31/2025","study_completion_date":" 05/31/2025","last_update_posted":"2024-06-10"}]